



TERSANO BULLETIN ON THE CORONAVIRUS

Saturday, March 21, 2020

With limited availability of the SARS-Cov-2 (Covid-19) for testing and biosafety requirements necessary to safely handle it, labs are only able to offer two methodologies for validation:

1. use a surrogate. Murine hepatitis Virus (MHV) is a coronavirus that is extremely infectious and has been used previously as a surrogate for SARS-Cov-2
2. the alternative approach, as per EPA guidelines, is to divide all viruses into three subgroups:
 - a) small non-enveloped (most difficult to kill viruses)
 - b) large non-enveloped
 - c) enveloped (SARS-Cov-2 and least difficult to kill viruses)

According to this hierarchy, if an antimicrobial product can kill a small, non-enveloped virus it will be effective at killing any large, non-enveloped virus or any enveloped virus. [EPA Guidance Document](#)

Tersano chose the alternative approach, performing our preliminary testing with dwell times of 5 minutes on a small, non-enveloped virus known as Canine Parvovirus (ATCC VR-2016). The results of these tests allow Tersano to claim that SAO™, including the iClean™ mini at 1ppm dissolved ozone, can kill over 99% of the Canine Parvovirus within 5 minutes.

For our next stage of testing we will work with laboratories as more options become available, including testing against SARS-Cov-2 directly. We anticipate these tests to be completed within 4 to 6 weeks.

We will, of course, keep every distributor and client updated with all information and testing in the coming weeks.

Please reach out with any questions or concerns.

Steve Hengsperger
President